Search

Your search keyword '"Saar, I."' showing total 458 results

Search Constraints

Start Over You searched for: Author "Saar, I." Remove constraint Author: "Saar, I."
458 results on '"Saar, I."'

Search Results

1. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

2. Cytokine-mediated CAR T therapy resistance in AML

6. Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

7. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

8. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy

11. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

12. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

13. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

15. WS06.06 Safety and efficacy of a nebulized phage cocktail in cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection: a phase 1b/2a randomized, double-blind, placebo-controlled study

16. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

17. Rapid manufacturing of non-activated potent CAR T cells

18. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients

21. Cancer immunotherapy comes of age and looks for maturity

22. Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

25. Interim Results of a Phase I/II Trial of Intermediate-Dose Post-Transplantation Cyclophosphamide after Reduced Intensity Conditioned HLA-Mismatched Bone Marrow Transplantation for Older or Unfit Patients

26. Post-Transplant Frailty Phenotype Predicts Survival

27. One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.

29. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration

31. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy

32. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies

35. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

36. One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant

37. Fungal Planet Description Sheets: 1478–1549

38. Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

40. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay

42. Fungal Planet description sheets: 1478–1549

43. Fungal Planet description sheets:1478–1549

44. Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation.

45. CD38 as a pan-hematologic target for chimeric antigen receptor T cells

46. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

47. CD38 as a pan-hematologic target for chimeric antigen receptor T cells

48. Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant

49. Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

50. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies

Catalog

Books, media, physical & digital resources